
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM S-1
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

IMPRIMIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

2834

(Primary Standard Industrial
Classification Code Number)

45-0567010

(I.R.S. Employer
Identification Number)

**437 S. Hwy 101, Suite 209
Solana Beach, CA 92075
(858) 433-2800**

(Address, including zip code, and telephone number, including
area code, of registrant's principal executive offices)

**Mark L. Baum
Chief Executive Officer
437 S. Hwy 101, Suite 209
Solana Beach, CA 92075
(858) 433-2800**

(Name, address, including zip code, and telephone number, including
area code, of agent for service)

Copies to:

Steven G. Rowles, Esq.
Jeannette V. Filippone, Esq.
Morrison & Foerster LLP
12531 High Bluff Drive, Suite 100
San Diego, California 92130
Tel: (858) 720-5100
Fax: (858) 720-5125

Kevin Friedmann, Esq.
Marc A. Jones, Esq.
Richardson & Patel LLP
405 Lexington Avenue, 49th Floor
New York, New York 10174
Tel: (212) 561-5559
Fax: (917) 591-6898

Approximate date of commencement of proposed sale to the public: As soon as possible after the effective date hereof.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. Registration No. 333-182846

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company)

Smaller reporting company

CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities to be Registered	Proposed Maximum Aggregate Offering Price (1)	Amount of Registration Fee (1)(2)
Common Stock	\$ 1,334,004	\$ 181.96
Total:	\$ 1,334,004	\$ 181.96

(1) Calculated pursuant to Rule 457(o) under the Securities Act of 1933.

(2) Represents only the additional amount of securities being registered. The Registrant previously registered an aggregate of \$9,774,996 of its shares on the Registrant’s Registration Statement on Form S-1 (File No. 333-182846) declared effective on February 7, 2013, for which a filing fee was previously paid.

The Registration Statement shall become effective upon filing with the Commission in accordance with Rule 462(b) under the Securities Act of 1933, as amended.

EXPLANATORY NOTE AND INCORPORATION BY REFERENCE

This registration statement is being filed to increase the dollar amount of securities registered under the registration statement on Form S-1 (Registration No. 333-182846) declared effective on February 7, 2013 (the “Initial Registration Statement”), by \$1,334,004 pursuant to Rule 462(b) of the Securities Act of 1933, as amended. In accordance with Rule 462(b), this registration statement incorporates by reference the Initial Registration Statement, including all amendments, supplements and exhibits thereto and all information incorporated by reference therein, other than the exhibits included herein.

PART II
INFORMATION NOT REQUIRED IN PROSPECTUS

Item 16. Exhibits

Exhibit Number	Description of Exhibit
5.1	Opinion of Morrison & Foerster LLP (filed herewith)
23.1	Consent of Independent Registered Public Accounting Firm, KMJ Corbin & Company LLP (filed herewith)
23.2	Consent of Morrison & Foerster LLP (including in Exhibit 5.1)
24.1	Power of Attorney (previously filed on the signature page to the Registration Statement on Form S-1 (File No. 333-182846) filed with the SEC on July 25, 2012)



SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Solana Beach, State of California, on February 7, 2013.

IMPRIMIS PHARMACEUTICALS, INC.

By: /s/ Mark L. Baum

Mark L. Baum, Chief Executive Officer
(Principal Executive Officer)

Date: February 7, 2013

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

<u>SIGNATURE</u>	<u>TITLE</u>	<u>DATE</u>
<u>/s/ Mark L. Baum</u> Mark L. Baum, Esq.	Chief Executive Officer and Director (Principal Executive Officer)	February 7, 2013
<u>/s/ Andrew R. Boll</u> Andrew R. Boll	Vice President of Accounting and Public Reporting (Principal Accounting & Financial Officer)	February 7, 2013
<u>/s/ Jeffrey J. Abrams*</u> Jeffrey J. Abrams, M.D.	Director	February 7, 2013
<u>/s/ Paul Finnegan*</u> Paul Finnegan, M.D., M.B.A.	Director	February 7, 2013
<u>/s/ Robert J. Kammer*</u> Robert J. Kammer, D.D.S.	Chairman of the Board of Directors	February 7, 2013

*By: /s/ Mark L. Baum

Mark L. Baum
Attorney-in-Fact

EXHIBIT INDEX

**Exhibit
Number**

Description of Exhibit

5.1	Opinion of Morrison & Foerster LLP (filed herewith)
23.1	Consent of Independent Registered Public Accounting Firm, KMJ Corbin & Company LLP (filed herewith)
23.2	Consent of Morrison & Foerster LLP (including in Exhibit 5.1)
24.1	Power of Attorney (previously filed on the signature page to the Registration Statement on Form S-1 (File No. 333-182846) filed with the SEC on July 25, 2012)



12531 HIGH BLUFF DRIVE
SAN DIEGO, CALIFORNIA
92130-2040

TELEPHONE: 858.720.5100
FACSIMILE: 858.720.5125

WWW.MOFO.COM

MORRISON & FOERSTER LLP
NEW YORK, SAN FRANCISCO,
LOS ANGELES, PALO ALTO,
SACRAMENTO, SAN DIEGO,
DENVER, NORTHERN VIRGINIA,
WASHINGTON, D.C.
TOKYO, LONDON, BRUSSELS,
BEIJING, SHANGHAI, HONG KONG
SINGAPORE

February 7, 2013

Imprimis Pharmaceuticals, Inc.
437 South Highway 101, Suite 209
Solana Beach, CA 92075

Re: Registration Statement on Form S-1
Filed pursuant to Rule 462(b) under the Securities Act of 1933

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-1 (the "Registration Statement") of Imprimis Pharmaceuticals, Inc., a Delaware corporation (the "Company"), to be filed with the Securities and Exchange Commission on February 7, 2013 pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the "Securities Act"), relating to the registration under the Securities Act of an additional 254,096 shares (the "Additional Shares") of the Company's common stock, \$0.001 par value per share (which includes shares subject to the underwriters' over-allotment option). An aggregate of 1,861,904 shares of the Company's common stock was registered pursuant to the Company's Registration Statement on Form S-1 (No. 333-182846), which was declared effective by the Commission on February 7, 2013. The Additional Shares are to be sold to the underwriters named in the Registration Statement for resale to the public.

As counsel to the Company, we have examined the proceedings taken by the Company in connection with the issuance by the Company of the Additional Shares. We are of the opinion that the Additional Shares to be offered and sold by the Company have been duly authorized and, when issued and sold by the Company in the manner described in the Registration Statement and in accordance with the resolutions adopted by the Board of Directors of the Company, will be legally issued, fully paid and nonassessable.

We hereby consent to the inclusion of this opinion as an exhibit to the Registration Statement and to the reference to our firm under the caption "Legal Matters" in the Registration Statement and the prospectus included or incorporated by reference therein.

Very truly yours,

/s/ Morrison & Foerster LLP

Morrison & Foerster LLP

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in this Registration Statement on Form S-1 filed pursuant to Rule 462(b) of the Securities Act of 1933 of our report dated February 23, 2012 (except for the effect of the retrospective application of the reverse stock split as described in Note 3, as to which the date is February 28, 2012) relating to the consolidated financial statements of Imprimis Pharmaceuticals, Inc. (formerly Transdel Pharmaceuticals, Inc.) and subsidiary (the "Company") as of December 31, 2011 and 2010 and for each of the two years in the period ended December 31, 2011 and for the period from July 24, 1998 (date of inception) through December 31, 2011 (which report expresses an unqualified opinion and includes an explanatory paragraph about the Company's ability to continue as a going concern) appearing in the Registration Statement (No. 333-182846) on Form S-1 and related Prospectus of the Company dated February 4, 2013, and to the reference to us under the heading "Experts" in the related Prospectus.

/s/ KMJ Corbin & Company LLP

KMJ Corbin & Company LLP

Costa Mesa, California

February 7, 2013